BTG.L - BTG plc

LSE - LSE Delayed Price. Currency in GBp
834.50
0.00 (0.00%)
At close: 4:35PM BST
Stock chart is not supported by your current browser
Previous Close834.50
Open835.00
Bid834.50 x 66000
Ask817.00 x 112600
Day's Range833.50 - 835.00
52 Week Range467.40 - 853.00
Volume275,014
Avg. Volume951,099
Market Cap3.234B
Beta (3Y Monthly)-0.11
PE Ratio (TTM)114.32
EPS (TTM)7.30
Earnings DateJun 17, 2019 - Jun 21, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date1998-07-13
1y Target Est9.64
  • Reuterslast month

    What's at stake for Europe Inc in a trade spat with Washington

    Europe's listed companies are expected to generate 1.2 trillion euros (£1.0 trillion) in revenue from the United States this year, highlighting what's at stake as global trade tensions grow and earnings and economic growth stall. Analysts and investors say that based on revenues, European companies are more vulnerable to a dispute than their competitors in the United States. U.S. President Donald Trump is due to decide by Saturday whether to impose duties on car imports, potentially posing another significant threat to global growth and denting Europe's prized auto sector.

  • Venous Leg Ulcer Registry Shows Promising Results for Varithena® Use in Wound Healing
    PR Newswire2 months ago

    Venous Leg Ulcer Registry Shows Promising Results for Varithena® Use in Wound Healing

    BOTHELL, WA , April 29, 2019 /PRNewswire/ -- BTG plc (LSE: BTG), the global specialist healthcare company, today highlighted the VIEW VLU Registry interim study results, presented at the International ...

  • Business Wire2 months ago

    Trial Finds Patients Receiving CroFab® Antivenom Less Likely to Use Opioids for Pain Control

    BTG plc (BTG.L), the global healthcare company, today announced the publication of a trial, "Antivenom Treatment is Associated with Fewer Patients Using Opioids after Copperhead Envenomation" in the Western Journal of Emergency Medicine (WestJEM). “In a randomized, double-blind, placebo-controlled, clinical trial of CroFab® for treatment of copperhead snakebite, patients that received CroFab® were less likely to use opioids for pain control during recovery,” said Dr. Charles Gerardo, Chief of Emergency Medicine at Duke University and expert in copperhead snake envenomation.

  • Moody's4 months ago

    Boston Scientific Corporation -- Moody's assigns Baa2 rating to Boston Scientific's notes

    Moody's Investors Service ("Moody's") assigned a Baa2 rating to the new senior unsecured notes offering of Boston Scientific Corporation ("Boston Scientific"). There are no changes to Moody's existing ratings of Boston Scientific including the Baa2 senior unsecured long-term rating and the Prime-2 short-term rating. Boston Scientific's Baa2 senior unsecured ratings reflects its meaningful scale in the medical device industry with revenues of approximately $10 billion.

  • PR Newswire4 months ago

    NHS England Expands Loco-regional Treatment Options for Colorectal Cancer Patients With Metastatic Disease

    LONDON , Feb. 5, 2019 /PRNewswire/ -- BTG plc (LSE: BTG), a global healthcare company, today announced that the NHS Specialised Services Commissioning Committee has agreed that, effective 1 April 2019 ...

  • PR Newswire5 months ago

    Australian Patient Treated With DC Bead LUMI™, the First Commercially Available Radiopaque Drug-Eluting Bead

    LONDON , January 21, 2019 /PRNewswire/ -- BTG plc (LSE: BTG), a global specialist healthcare company, today announced the treatment of an Australian patient with DC Bead LUMI™, a next-generation development ...

  • PR Newswire5 months ago

    BTG and OMNY Partner to Improve Treatment of Snake Bite Victims

    BTG, the global healthcare company, is partnering with OMNY to improve visibility of inventory data for its antivenom product CroFab® using distributed ledger technology. This makes it important to understand and manage antivenom stock levels. CroFab® is the only FDA-approved product to treat all North American pit viper envenomations in adult and pediatric patients.[ii],[iii] It is proven to control local, systemic, and hematologic effects of envenomation[ii], [iv], * and 95% of patients showed a clinical response 1 hour after initial control[v].

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of BTG.L earnings conference call or presentation 13-Nov-18 9:30am GMT

    Half Year 2019 BTG PLC Earnings Presentation

  • PR Newswire6 months ago

    BTG Announces National Reimbursement for TheraSphere® in France

    BTG plc (BTG.L), a global specialist healthcare company, today announced that the French Ministry of Health and Social Affairs will reimburse TheraSphere® for patients with liver cancer who meet certain criteria. "This reimbursement decision provides access to a new treatment option for some of the estimated 9,600 people diagnosed with liver cancer in France each year[iv]," said Jane Lapon, VP Global Market Access at BTG.

  • Gold ETF Holdings Are on the Rise
    Market Realist6 months ago

    Gold ETF Holdings Are on the Rise

    According to a report by the World Gold Council (or WGC), holdings in gold ETFs rose for the second consecutive month in November to 21.2 tons to a total of 2,365 tons. It also said that the global gold-backed ETF flows are now positive in US dollar (UUP) terms for the year. ETF flows were positive for the first time in four months. The renewed buying interest from investors was on account of increased market volatility and the equity market sell-off.

  • Business Wire6 months ago

    Arizona Patients Successfully Receive the World’s First Bioconvertible IVC Filter Commercially Offered In US

    BTG plc (BTG.L), the global healthcare company, today announced the first patients outside of a clinical trial have been successfully implanted with the BTG Sentry device – the world’s first bioconvertible IVC filter. The BTG Sentry filter is designed to provide protection from Pulmonary Embolism (PE) for the period of transient risk and then bioconvert to leave a patent, unobstructed IVC lumen, eliminating the need to retrieve and addressing the typical filter-related complications associated with conventional IVC filters. Dr. Ayad K.M. Agha, Director of Interventional Radiology and an interventional radiologist at Cardiovascular Interventional Radiology Centers in Phoenix, Arizona, who performed the procedure on one of his patients, said: “Traditional IVC filters are sometimes associated with a variety of concerns.

  • Moody's7 months ago

    Boston Scientific Corporation -- Moody's affirms Boston Scientific's Baa2 senior unsecured rating, stable outlook

    Moody's Investors Service ("Moody's") today affirmed Boston Scientific Corporation's Baa2 senior unsecured ratings and its Prime-2 commercial paper rating. The affirmation of the ratings follows Boston Scientific's announcement that it has reached an agreement to acquire BTG Plc, a UK-based medical products company. Under the terms of the offer, Boston Scientific will acquire BTG for approximately GBP 3.3 billion ($4.2 billion at current exchange rates).

  • Reuters7 months ago

    Brexit woes push FTSE to three-week lows; investors dump banks, oil

    UK shares fell to three-week lows on Tuesday as investors dumped financial, oil and mining stocks amid renewed fears about Brexit and Rome's budget showdown with Brussels, and Wall Street gloom across tech and retail spread across Europe. The FTSE 100 (.FTSE) ended the day down 0.8 percent, its third straight daily loss, with sentiment also hurt by heavy losses in the euro zone after a report Apple has cut production triggered a global rout in tech stocks. While the political drama of last week has largely calmed, investors worried anew about UK Prime Minister Theresa May's struggle to get her draft Brexit deal passed in Brussels and at home, with banks bearing the brunt of the selling.

  • TheStreet.com7 months ago

    Boston Scientific to Buy Britain's BTG for $4.2 Billion

    Boston Scientific Corp. on Tuesday agreed to buy British healthcare company BTG plc in a $4.2 billion deal. The Marlborough, Mass.-based medical device maker offered $10.77 for each BTG share, representing a premium of 36.

  • Reuters7 months ago

    Boston Scientific builds medical tech with $4.2 billion BTG deal

    U.S. medical device maker Boston Scientific Corp (BSX.N) has agreed to buy Britain's BTG Plc (BTG.L) for 3.3 billion pounds in cash, adding technology to fight cancer and other serious diseases to its portfolio. Boston Scientific - best known for making stents to prop open clogged heart arteries - has agreed to pay 840 pence per share, representing a premium of 36.6 percent to BTG's previous closing price, the companies said on Tuesday. Shares of BTG soared by a third to 825p by 1200 GMT after touching 832p, their highest level since Jan. 2015.

  • Brexit Makes a $4.2 Billion Black Friday Bargain
    Bloomberg7 months ago

    Brexit Makes a $4.2 Billion Black Friday Bargain

    Boston Scientific Corp. has seen its chance and agreed to buy London-based BTG Plc for 3.3 billion pounds ($4.2 billion). If the deal is consummated, the British maker of medical devices will join the growing list of internationally-flavored U.K. companies falling prey to overseas bidders. This has been a rough year for BTG.

  • Reuters7 months ago

    Boston Scientific offers to buy UK's BTG for about $4.24 billion

    U.S. medical device maker Boston Scientific Corp said it offered to buy British pharmaceutical firm BTG Plc for about 3.3 billion pounds ($4.24 billion) in cash. The offer of 840 pence in cash per share represents a premium of 36.6 percent to BTG's close of 615 pence on Monday. BTG said it plans to recommend the deal to its shareholders as it considers the terms to be fair and reasonable.